Attacking cancer at its foundation

Nature Medicine

Volumn 15, Issue 10, 2009, Pages 1153-1157

  Lydon, Nicholas ^a  

^a Grant Biopharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; ERBSTATIN; ERLOTINIB; FLAVONE DERIVATIVE; GEFITINIB; IMATINIB; ISOFLAVONE DERIVATIVE; PROTEIN TYROSINE KINASE; STAUROSPORINE; SUNITINIB; TRASTUZUMAB; VANDETANIB;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN STRUCTURE;

ACADEMIC MEDICAL CENTERS; AWARDS AND PRIZES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; UNITED STATES;

EID: 70350433460     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1009-1153     Document Type: Note

References (64)

1. Rous, P. & Oliver, J. J. Exp. Med. 28, 696 (1910).
2. Hunter, T. & Sefton, B. Proc. Natl. Acad. Sci. USA 77, 1311-1315 (1980).
3. Downward, J. et al. Nature 307, 521 (1984).
4. Doolittle, R.F. et al. Science 221, 275-277 (1983).
5. Waterfield, M.D. et al. Nature 304, 35 (1983).
6. Nowell, P.C. & Hungerford, D.A. Science 142, 1497 (1960).
7. Rowley, J.D. Nature 243, 290-293 (1973).
8. Castagna, M. et al. J. Biol. Chem. 257, 7847-7851 (1982).
9. Hunter, T. Sci. Am. 251, 70-79 (1984).
10. Hanks, S.K. et al. Science 241, 42-52 (1988).
11. Hunter, T. Cell 50, 823-829 (1987).
12. Blume-Jensen, P. & Hunter, T. Nature 411, 355 (2001).
13. Foulkes, J.G. et al. J. Biol. Chem. 260, 8070-8077 (1985).
14. Lydon, N.B. et al. Oncogene Res. 5, 161-173 (1990).
15. Lydon, N.B. et al. Biochem. J. 287, 985-993 (1992).
16. McGlynn, E. et al. in Baculovirus and recombinant protein production processes. (eds. Vlak, J.M., Bernard, A. and Schaeger, E.-J.) 209-216 (Editiones Roche, Basel, 1992).
17. McGlynn, E. et al. J. Cell. Biochem. 49, 239-250 (1992).
18. McGlynn, E. et al. Eur. J. Biochem. 207, 265-275 (1992).
19. Druker, B.J. et al. N. Engl. J. Med. 321, 1383-1391 (1989).
20. Farley, K., Mett, H., McGlynn, E., Murray, B. & Lydon, N.B. Anal. Biochem. 203, 151-157 (1992)
21. Cohen, P. Nat. Rev. Drug Discov. 1, 309 (2002)
22. Levitzki, A. FASEB J. 6, 3275 (1992).
23. Traxler, P. Exp. Opin. Ther. Pat. 7, 571-588 (1997).
24. Umezawa, H. et al. J. Antibiot. 39, 170-173 (1986).
25. Graziani, Y. et al. Biochim. Biophys. Acta 714, 415-421 (1982).
26. Tamaoki, T. et al. Biochem. Biophys. Res. Commun. 135, 397-402 (1986).
27. Geissler, J.F. et al. Cancer Res. 56, 100-104 (1996).
28. Karaman, M.W. et al. Nat. Biotechnol. 26, 127 (2008).
29. Yaish, P. et al. Science 242, 933-935 (1988).
30. Zimmermann, J. et al. Arch. Pharm. Pharm. Med. Chem. 329, 371-376 (1996).
31. Zimmermann, J. et al. Bioorg. Med. Chem. Lett. 6, 1221-1226 (1996).
32. Buchdunger, E. et al. Cancer Res. 56, 100-104 (1996).
33. Knighton, D.R. et al. Science 253, 407-414 (1991).
34. Druker, B.J. & Lydon, N.B. J. Clin. Invest. 105, 3-7 (2000).
35. Schindler, T. et al. Science 289, 1938-1942 (2000).
36. Huse, M. & Kuriyan, J. Cell 109, 275 (2002).
37. Fabian, M.A. et al. Nat. Biotechnol. 23, 329 (2005).
38. Druker, B.J. et al. Nat. Med. 2, 561-566 (1996).
39. Carroll, M. et al. Blood 90, 4947-4952 (1997).
40. Heinrich, M.C. et al. Blood 96, 925-932 (2000).
41. Buchdunger, E. et al. J. Pharmacol. Exp. Ther. 295, 139-145 (2000).
42. Demetri, G.D. et al. N. Engl. J. Med. 347, 472-480 (2002).
43. Druker, B.J. et al. N. Engl. J. Med. 344, 1031-1037 (2001).
44. Heinrich, M.C, Blanke, CD., Druker, B.J. & Corless, C.L. J. Clin. Oncol. 20, 1692-1703 (2002).
45. Siddiqui, M.A. & Scott, L.J. Drugs 67, 805-820 (2007).
46. Golub, T.R., Barker, G.F., Lovett, M. & Gilliland, D.G. Cell 77, 307-316 (1994).
47. Apperley, J.F. et al. N. Engl. J. Med. 347, 481-487 (2002).
48. Magnusson, M.K., Meade, K.E., Nakamura, R., Barrett, J. & Dunbar, C.E. Blood 100, 1088-1091 (2002).
49. Gleich, G.J., Leiferman, K.M., Pardanani, A., Tefferi, A. & Butterfield, J.H. Lancet 359, 1577-1578 (2002).
50. Cools, J. et al. N. Engl. J. Med. 348, 1201-1214 (2003).
51. Herbst, R.S. et al. Nat. Rev. Cancer 4, 956 (2004)
52. Arteaga, C.L. Nat. Med. 10, 577 (2004)
53. Kris, M.G. J. Am. Med. Assoc. 290, 2149-2158 (2003).
54. Paez, J.G. et al. Science 304, 1497-1500 (2004)
55. Lynch, T.J. N. Engl. J. Med. 350, 2129-2139 (2004).
56. Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
57. Pao, W. et al. PLoS Med. 2, e73 (2005).
58. Kobayashi, S. et al. N. Engl. J. Med. 352, 786-792 (2005).
59. Gorre, M.E. et al. Science 293, 876-880 (2001).
60. Hanahan, D. & Weinberg, R.A. Cell 100, 57 (2000).
61. Liu, Y. & Grey, N.S. Nat. Chem. Biol. 2, 358-364 (2006).
62. Wedge, S.R. et al. Cancer Res. 62, 4645-4655 (2002).
63. Heymach, J.V. Br. J. Cancer 92, S14-S20 (2005).
64. Goldstein, D.M. et al. Nat. Rev. Drug Discov. 7, 391 (2008)